The CANTATA trial compares chemotherapy drugs cabazitaxel and docetaxel for prostate cancer that has spread to other parts of the body. Men taking part have prostate cancer that has started to get worse after previously having had hormone therapy and docetaxel chemotherapy.
If prostate cancer has spread outside the prostate gland, doctors often treat it with hormone therapy. This can work very well, but at some stage the cancer may no longer respond to the hormone therapy and start to grow again. In this case chemotherapy with a drug called docetaxel is often offered. If the cancer returns again, docetaxel may again be offered as a ‘re-challenge’.
Alternatively, cabazitaxel is a newer chemotherapy drug that may be used for the re-challenge.
The researchers are comparing cabazitaxel and a docetaxel re-challenge, specifically to see which treatment helps men more and to learn more about the side-effects.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
| Chief Investigator: |
Professor Nicholas James |
| Sponsor: |
University of Birmingham |
| Funders: |
Educational Grant from SANOFI and endorsed by Cancer Research UK |
| Disease Site: |
Prostate cancer |
| Trial Type: |
Chemotherapy / Phase II |
| Status: |
Follow-up |
| UKCRN Study ID: (if applicable) |
13741 |
| Open to new sites? |
No |
| Recruitment start date: |
07 March 2013 |
| Recruitment end date |
12 January 2016 |
| CRCTU Trial Management Team: |
Team A |
| Trial E-mail Address: |
cantata@trials.bham.ac.uk |